Akagawa et al. showed that at peritoneally disseminated sites of PDA peritoneal myofibroblasts that are positive for smooth muscle actin (αSMA+) promote dissemination and thus may be a potential new therapeutic target [121]. This evidence concerns the gene ACTA1 and Patent ductus arteriosus.